ImmunityBio And NCartes Enter Collaboration Agreement Aimed At Automating And Streamlining The Data Fulfillment Process For Clinical Trials; The Goal Of The Collaboration Is To Make This Essential Process Easier, Faster, And Less Expensive For ImmunityBio's Trial Investigators

ImmunityBio, Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational cloud software platform provider, announced a collaboration agreement aimed at automating and streamlining the data fulfillment process for clinical trials. The goal of the collaboration is to make this essential process easier, faster, and less expensive for ImmunityBio's trial investigators.

The vast majority of clinical trials today gather data manually at clinical research sites. The data is then entered by hand into Electronic Data Capture (EDC) systems used by clinical trial sponsors. This process is time-consuming, costly, and creates the potential for errors that can further delay trial results. This new collaboration will instead rely on using digital information available in source electronic medical record (EMR) systems to directly populate EDC systems.